Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study.

Luz P, Lopes-Brás R, de Pinho IS, Patel V, Esperança-Martins M, Gonçalves L, Gonçalves J, Freitas R, Simão D, Galnares MR, Criado SA, Nobre A, Medina EAG, Vega IMS, de Sousa RT, Costa L, Gregório J, Costa JG, Fernandes AS

Open source

DOI: 10.1007/s12094-025-03937-7
Published: 2025 Nov
Container: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12094-025-03937-7,
  title = {Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study.},
  author = {Luz P and Lopes-Brás R and de Pinho IS and Patel V and Esperança-Martins M and Gonçalves L and Gonçalves J and Freitas R and Simão D and Galnares MR and Criado SA and Nobre A and Medina EAG and Vega IMS and de Sousa RT and Costa L and Gregório J and Costa JG and Fernandes AS},
  year = {2025},
  journal = {Clinical \& translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
  doi = {10.1007/s12094-025-03937-7},
  url = {https://doi.org/10.1007/s12094-025-03937-7}
}

RIS

TY  - JOUR
TI  - Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study.
AU  - Luz P
AU  - Lopes-Brás R
AU  - de Pinho IS
AU  - Patel V
AU  - Esperança-Martins M
AU  - Gonçalves L
AU  - Gonçalves J
AU  - Freitas R
AU  - Simão D
AU  - Galnares MR
AU  - Criado SA
AU  - Nobre A
AU  - Medina EAG
AU  - Vega IMS
AU  - de Sousa RT
AU  - Costa L
AU  - Gregório J
AU  - Costa JG
AU  - Fernandes AS
PY  - 2025
JO  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
DO  - 10.1007/s12094-025-03937-7
UR  - https://doi.org/10.1007/s12094-025-03937-7
ER  -

APA

P, L., R, L., IS, D. P., V, P., M, E., L, G., J, G., R, F., D, S., MR, G., SA, C., A, N., EAG, M., IMS, V., RT, D. S., L, C., J, G., JG, C., & AS, F. (2025). Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. https://doi.org/10.1007/s12094-025-03937-7

Source records

pubmed · retrieved 2026-09-26T21:03:12.597Z